We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.9B
1-Year Est. Return 121.13%
This Fund
S&P 500
This Quarter Est. Return
+0.48%
1 Year Est. Return
+121.13%
3 Year Est. Return
+281.43%
5 Year Est. Return
+350.91%
10 Year Est. Return
–
AUM
$1.09B
AUM Growth
+$103M
Cap. Flow
+$76.4M
Cap. Flow %
7.03%
Top 10 Hldgs %
55.27%
Holding
75
New
18
Increased
23
Reduced
22
Closed
7

Top Buys

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$24.3M
2
UNH icon
UnitedHealth
UNH
+$23.2M
3
RVTY icon
Revvity
RVTY
+$19.9M
4
AVTR icon
Avantor
AVTR
+$19.2M
5
ILMN icon
Illumina
ILMN
+$16.1M

Top Sells

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$18.9M
2
HQY icon
HealthEquity
HQY
+$18.6M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$18.5M
4
NTRA icon
Natera
NTRA
+$15.2M
5
GSK icon
GSK
GSK
+$14.6M

Sector Composition

Rank Sector Weight
1 Healthcare 91.21%
2 Financials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
1
Natera
NTRA
$37.5B
$135M 12.37%
796,375
-97,346
-11% -$15.2M
QQQ icon
2
PUT
Invesco QQQ Trust
QQQ
$455B
$95M 8.74%
172,200
+48,600
+39% +$24.2M
GSK icon
3
GSK
GSK
$103B
$86.1M 7.92%
2,242,388
-380,858
-15% -$14.6M
VERA icon
4
Vera Therapeutics
VERA
$2.54B
$56.1M 5.16%
2,383,055
+484,251
+26% +$10.9M
RVTY icon
5
Revvity
RVTY
$12.3B
$49.4M 4.54%
510,330
+211,243
+71% +$19.9M
PCVX icon
6
Vaxcyte
PCVX
$7.89B
$42.2M 3.88%
1,298,514
+741,444
+133% +$24.3M
HCA icon
7
HCA Healthcare
HCA
$84.8B
$38.3M 3.52%
99,983
-52,519
-34% -$18.9M
SNDX icon
8
Syndax Pharmaceuticals
SNDX
$1.84B
$38.1M 3.5%
4,065,355
-146,915
-3% -$1.62M
BRKR icon
9
Bruker
BRKR
$9.2B
$34.6M 3.18%
839,284
+340,077
+68% +$13.1M
VRDN icon
10
Viridian Therapeutics
VRDN
$2.13B
$26.6M 2.45%
1,902,539
+524,865
+38% +$7.12M
IONS icon
11
Ionis Pharmaceuticals
IONS
$9.35B
$23.3M 2.14%
588,900
+71,879
+14% +$2.35M
CNC icon
12
Centene
CNC
$31.3B
$21.6M 1.99%
398,726
+58,387
+17% +$3.42M
INSP icon
13
Inspire Medical Systems
INSP
$1.42B
$21.3M 1.96%
164,473
-21,952
-12% -$3.18M
CYH icon
14
Community Health Systems
CYH
$385M
$20.9M 1.92%
6,144,384
-2,313,636
-27% -$7.44M
AVTR icon
15
Avantor
AVTR
$7.81B
$20.5M 1.89%
1,526,164
+1,403,341
+1,143% +$19.2M
TECH icon
16
Bio-Techne
TECH
$11.2B
$20.3M 1.87%
394,139
+114,022
+41% +$5.73M
TVTX icon
17
Travere Therapeutics
TVTX
$5.33B
$19.5M 1.79%
1,315,033
+498,779
+61% +$8.27M
ZIMV
18
DELISTED
ZimVie
ZIMV
$19.4M 1.79%
2,079,380
– –
UNH icon
19
UnitedHealth
UNH
$382B
$18.9M 1.74%
+60,736
New +$23.2M
ILMN icon
20
Illumina
ILMN
$29.4B
$18.9M 1.74%
+198,584
New +$16.1M
TEVA icon
21
Teva Pharmaceuticals
TEVA
$35.9B
$17.6M 1.62%
1,052,881
-357,884
-25% -$5.78M
CLDX icon
22
Celldex Therapeutics
CLDX
$2.77B
$17.1M 1.57%
838,736
+142,237
+20% +$2.77M
UTHR icon
23
United Therapeutics
UTHR
$26.3B
$17.1M 1.57%
59,366
+1,877
+3% +$561K
HQY icon
24
HealthEquity
HQY
$7.91B
$16.3M 1.5%
155,868
-196,108
-56% -$18.6M
IQV icon
25
IQVIA
IQV
$34.7B
$15.4M 1.41%
+97,604
New +$14.7M
1
2 3

Similar funds

DCP
Distillate Capital Partners Chicago, Illinois $1.9B AUM 2.22% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $1.89B AUM 14.55% 1-Year Est. Return
OPCM
Osborne Partners Capital Management San Francisco, California $1.89B AUM 16.21% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
RCA
Resonant Capital Advisors Madison, Wisconsin $1.9B AUM 14.38% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $1.91B AUM 24.91% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
TF
Trek Financial Scottsdale, Arizona $1.88B AUM 41.21% 1-Year Est. Return

Eversept Partners's Q2 2025 Portfolio in Review

As of Q2 2025, Eversept Partners held 75 positions worth $1.09B, up 10% from $985M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Eversept Partners deployed $76.4M of net new capital in Q2 2025, opening 18 new positions and adding to 23 existing holdings. Its largest new stake was UnitedHealth: 60,736 shares worth $18.9M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 89% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was HCA Healthcare, an estimated $18.9M trimmed.

  • Eversept Partners's largest Q2 2025 buy was UnitedHealth: 60,736 shares worth $18.9M.
  • Eversept Partners added most to Vaxcyte in Q2 2025, an estimated $24.3M increase.
  • Eversept Partners's biggest Q2 2025 reduction was HCA Healthcare, cutting an estimated $18.9M.
  • Eversept Partners fully exited Neurocrine Biosciences in Q2 2025, selling an estimated $18.5M.
  • Eversept Partners's ten largest holdings make up 55% of its $1.09B portfolio in Q2 2025.
  • Eversept Partners opened 18 new positions and closed 7 in Q2 2025.
  • Eversept Partners's portfolio value rose 10% quarter-over-quarter to $1.09B.

Based on Eversept Partners's 13F filing for Q2 2025, filed 14 Aug 2025.